GlassScriptPhysician profile
Lacy R Stark
NPI 1922510205
$7,345.52
in general payments reported to CMS, 2019-2025
59 companies · $2,173 in 2025
The $2,173 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $825 · 2022: $1,034 · 2023: $1,303 · 2024: $2,010 · 2025: $2,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,453 · Education: $33.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,453.26 |
| Education | $33.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,981.63 | 2021-2025 | |
| Biogen, INC. | $380.34 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $356.28 | 2021-2025 | |
| Pfizer INC. | $343.12 | 2023-2025 | |
| Sk Life Science, INC. | $340.49 | 2021-2025 | |
| Ucb, INC. | $279.46 | 2021-2025 | Briviact, Rystiggo |
| Amneal Pharmaceuticals LLC | $260.76 | 2021-2025 | Crexont, Rytary, Ongentys |
| Lundbeck LLC | $219.24 | 2021-2025 | Vyepti, Rexulti |
| Acadia Pharmaceuticals INC | $205.14 | 2023-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $185.52 | 2021-2024 | Austedo Xr, Austedo |
| Amgen INC. | $185.41 | 2021-2025 | Uplizna |
| Lilly USA, LLC | $172.03 | 2021-2024 | Reyvow, Emgality, Kisunla |
| Alexion Pharmaceuticals, INC. | $143.64 | 2023-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $137.71 | 2022-2025 | |
| Janssen Biotech, INC. | $112.03 | 2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacy Stark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.